EP0796277A4 - Reagentien und verfahren zur überexpression von mütierten epidermalen wachstumsfaktorrezeptoren - Google Patents

Reagentien und verfahren zur überexpression von mütierten epidermalen wachstumsfaktorrezeptoren

Info

Publication number
EP0796277A4
EP0796277A4 EP95943342A EP95943342A EP0796277A4 EP 0796277 A4 EP0796277 A4 EP 0796277A4 EP 95943342 A EP95943342 A EP 95943342A EP 95943342 A EP95943342 A EP 95943342A EP 0796277 A4 EP0796277 A4 EP 0796277A4
Authority
EP
European Patent Office
Prior art keywords
egf receptor
reagents
processes
growth factor
epidermal growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP95943342A
Other languages
English (en)
French (fr)
Other versions
EP0796277A1 (de
EP0796277B1 (de
Inventor
Albert J Wong
David K Moscatello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP0796277A1 publication Critical patent/EP0796277A1/de
Publication of EP0796277A4 publication Critical patent/EP0796277A4/de
Application granted granted Critical
Publication of EP0796277B1 publication Critical patent/EP0796277B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
EP95943342A 1994-11-28 1995-11-28 Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin Expired - Lifetime EP0796277B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34752094A 1994-11-28 1994-11-28
US347520 1994-11-28
PCT/US1995/015401 WO1996016988A1 (en) 1994-11-28 1995-11-28 Reagents and processes for targeting mutant epidermal growth factor receptors

Publications (3)

Publication Number Publication Date
EP0796277A1 EP0796277A1 (de) 1997-09-24
EP0796277A4 true EP0796277A4 (de) 2001-01-24
EP0796277B1 EP0796277B1 (de) 2004-03-24

Family

ID=23364052

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95943342A Expired - Lifetime EP0796277B1 (de) 1994-11-28 1995-11-28 Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin

Country Status (7)

Country Link
US (1) US6224868B1 (de)
EP (1) EP0796277B1 (de)
JP (2) JP4620808B2 (de)
AT (1) ATE262586T1 (de)
CA (1) CA2206343C (de)
DE (1) DE69532767T2 (de)
WO (1) WO1996016988A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
US5914269A (en) 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
JP2003506041A (ja) * 1999-07-30 2003-02-18 アメリカ合衆国 ヒトｐ５３変異およびヒトｐ５３変異の機能的同定のための酵母遺伝子系
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2001068711A1 (en) * 2000-03-10 2001-09-20 Thomas Jefferson University Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample
US6444465B1 (en) 2000-09-29 2002-09-03 Isis Pharmaceuticals, Inc. Antinsense modulation of Her-1 expression
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
EP1575500A4 (de) * 2002-07-12 2007-01-03 Univ Johns Hopkins Mesothelin-vakzine und model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US7084246B2 (en) * 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AU2011265359B9 (en) * 2003-06-27 2014-04-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AU2015242981B2 (en) * 2003-06-27 2017-10-19 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AU2012268864B2 (en) * 2003-06-27 2016-01-21 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
CN103463630A (zh) * 2005-11-02 2013-12-25 杜克大学 同时的化学疗法和免疫疗法
MX2009007987A (es) 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
US9340601B2 (en) * 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
US8753630B2 (en) * 2008-02-12 2014-06-17 The Board Of Trustees Of The Leland Stanford Junior University Using EGFRvIII to identify and target cancer stem cells
US8318693B2 (en) 2008-09-02 2012-11-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mutant EGFR gene
MX337070B (es) 2009-12-22 2016-02-11 Celldex Therapeutics Inc Método para preparar un conjugado klh-egfrviii.
CN103415620B (zh) * 2010-11-17 2016-10-12 艾杜罗生物科技公司 诱导针对EGFRvIII的免疫应答的方法和组合物
EP2879705A4 (de) 2012-08-02 2016-08-03 Univ Leland Stanford Junior Peptidimpfstoffe auf basis der egfrviii-sequenz zur behandlung von tumoren
WO2015142713A1 (en) * 2014-03-17 2015-09-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for reducing c/ebp homologous protein activity in myeloid-derived suppressor cells
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
EP3239177B1 (de) * 2014-11-25 2021-03-17 Pharmabcine Inc. Neuartiger egfrviii-antikörper und zusammensetzung damit
CR20170507A (es) 2015-04-13 2018-02-13 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.
TW201704267A (zh) 2015-04-13 2017-02-01 奧都羅生技公司 用於治療癌症的免疫性融合蛋白
WO2017142294A1 (ko) * 2016-02-15 2017-08-24 사회복지법인 삼성생명공익재단 EGFRvIII에 대한 항체 및 이의 용도
CN109476738A (zh) * 2016-02-15 2019-03-15 社会福祉法人三星生命公益财团 抗EGFRvIII的抗体及其用途
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003489A1 (en) * 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690814B2 (ja) * 1991-09-03 1997-12-17 山之内製薬株式会社 ピラゾロトリアゾール誘導体
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003489A1 (en) * 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GARCIA DE PALAZZO I. ET AL.: "Expression of mutated Epidermal Growth Factor Receptor by non-small cell lung carcinomas", CANCER RES., vol. 53, 15 July 1993 (1993-07-15), pages 3217 - 3220, XP002153548 *
HUMPHREY P A ET AL: "ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207 - 4211, XP000133024, ISSN: 0027-8424 *
RIEDEL H. ET AL.: "Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts", PROC.NATL. ACAD. SCI. USA, vol. 85, March 1988 (1988-03-01), pages 1477 - 1481, XP002148731 *
VELU T.J. ET AL.: "Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay.", J. CELL. BIOCHEM., vol. 39, 1989, pages 153 - 166, XP000946629 *
WIKSTRAND C J ET AL: "MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 55, 15 July 1995 (1995-07-15), pages 3140 - 3148, XP002074673, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
DE69532767T2 (de) 2004-08-12
ATE262586T1 (de) 2004-04-15
DE69532767D1 (en) 2004-04-29
JP2007297398A (ja) 2007-11-15
WO1996016988A1 (en) 1996-06-06
JP4620808B2 (ja) 2011-01-26
US6224868B1 (en) 2001-05-01
CA2206343C (en) 2009-04-07
CA2206343A1 (en) 1996-06-06
JPH10509878A (ja) 1998-09-29
EP0796277A1 (de) 1997-09-24
EP0796277B1 (de) 2004-03-24

Similar Documents

Publication Publication Date Title
EP0796277A4 (de) Reagentien und verfahren zur überexpression von mütierten epidermalen wachstumsfaktorrezeptoren
NZ331176A (en) Receptor protein designated 2F1, DNA encoding 2F1, preparation and use thereof
MX9804358A (es) Apoptosis inducida por el anticuerpo monoclonal anti-her2.
IL134842A0 (en) Method of delivering genes to antigen presenting cells of the skin
BRPI0012196B8 (pt) artigo industrializado
BR0110610A (pt) Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
EP1340765A3 (de) Invertierte Chimäre und Hybrid-Oligonukleotide
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
EP0815125A4 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
EP0804563A4 (de) Konstrukt zur bildung von antisense oligonucleotiden
DE60116753D1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
DE69830143D1 (en) Phosphodiesterase 8
WO1998022510A3 (en) Methods for the production of chicken monoclonal antibodies
NZ292019A (en) Haemophilus adherence and penetration proteins and vaccines therefrom
HUT76535A (en) Supression of tumor cell growth by syndecan-1 ectodomain
NZ515603A (en) Method of producing catalytic antibodies in a human
GB9814284D0 (en) Stepped rate shaping fuel injector
GB2326643A (en) Precursors of catalytic antibodies
EP1512755A3 (de) Marker für Prostatakrebs
WO1999025375A8 (en) DIRECT CYTOTOXIC ACTIVITY BY ANTI-hCG MONOCLONAL ANTIBODIES
DE59611293D1 (de) Protein mit dnase-aktivität

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/12 A, 7C 12N 5/10 B, 7C 07K 14/71 B, 7C 07K 16/28 B, 7C 07K 14/70 B, 7A 61K 38/17 B, 7C 12N 15/86 -

A4 Supplementary search report drawn up and despatched

Effective date: 20001207

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030325

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/86 -

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 38/17 B

Ipc: 7C 07K 14/70 B

Ipc: 7C 07K 16/28 B

Ipc: 7C 07K 14/71 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 12N 15/12 A

RTI1 Title (correction)

Free format text: FUSION JUNCTION TYPE III MUTANT EGF RECEPTOR PEPTIDE TUMOUR VACCINE

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040324

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20040324

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040324

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040324

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69532767

Country of ref document: DE

Date of ref document: 20040429

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040624

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040624

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040705

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: R. A. EGLI & CO. PATENTANWAELTE

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041130

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20041228

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040824

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20141118

Year of fee payment: 20

Ref country code: GB

Payment date: 20141127

Year of fee payment: 20

Ref country code: DE

Payment date: 20141128

Year of fee payment: 20

Ref country code: CH

Payment date: 20141127

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69532767

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20151127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151127